Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis
Background: Transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) may enhance the efficacy of treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, it remains unclear. We aim to evaluate the efficacy of TACE combined with TKIs....
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/1/96 |
| _version_ | 1827626867724648448 |
|---|---|
| author | Jia Deng Ziyue Liao Jian Gao |
| author_facet | Jia Deng Ziyue Liao Jian Gao |
| author_sort | Jia Deng |
| collection | DOAJ |
| description | Background: Transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) may enhance the efficacy of treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, it remains unclear. We aim to evaluate the efficacy of TACE combined with TKIs. Methods: A thorough literature search was performed on major databases since their inception until October 2022. Based on the eligibility criteria, eight studies (2103 patients) were included. Results: Meta-analysis showed that TACE+sorafenib/apatinib had a better tumor response (objective response rate (ORR): RR = 4.85, 95% CI 2.68–8.75, disease control rate (DCR): RR = 3.23, 95% CI 1.88–5.56), and prolonged OS (HR = 0.50, 95%CI 0.42–0.60, <i>p</i> < 0.00001) than TACE alone. TACE+lenvatinib was stronger than TACE+sorafenib in ORR (60.7% vs. 38.9%) and TTP (HR = 0.61, 95% CI 0.43–0.86), whereas it was similar in DCR (96.4% vs. 96.3%) and OS (HR = 0.70 95% CI 0.46–1.05). Conclusions: TACE plus sorafenib or apatinib was superior to TACE alone for hepatocellular carcinoma with PVTT; no significant advantage was found between TACE+lenvatinib and TACE+sorafenib, although TACE+lenvatinib performed better in terms of ORR and TTP. |
| first_indexed | 2024-03-09T13:04:34Z |
| format | Article |
| id | doaj.art-362f5fdede42400bb3e9e67f16767b0f |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-09T13:04:34Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-362f5fdede42400bb3e9e67f16767b0f2023-11-30T21:50:13ZengMDPI AGCurrent Oncology1198-00521718-77292023-01-013011243125410.3390/curroncol30010096Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-AnalysisJia Deng0Ziyue Liao1Jian Gao2Second Clinical College, Chongqing Medical University, Chongqing 400000, ChinaSecond Clinical College, Chongqing Medical University, Chongqing 400000, ChinaDepartment of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400000, ChinaBackground: Transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) may enhance the efficacy of treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, it remains unclear. We aim to evaluate the efficacy of TACE combined with TKIs. Methods: A thorough literature search was performed on major databases since their inception until October 2022. Based on the eligibility criteria, eight studies (2103 patients) were included. Results: Meta-analysis showed that TACE+sorafenib/apatinib had a better tumor response (objective response rate (ORR): RR = 4.85, 95% CI 2.68–8.75, disease control rate (DCR): RR = 3.23, 95% CI 1.88–5.56), and prolonged OS (HR = 0.50, 95%CI 0.42–0.60, <i>p</i> < 0.00001) than TACE alone. TACE+lenvatinib was stronger than TACE+sorafenib in ORR (60.7% vs. 38.9%) and TTP (HR = 0.61, 95% CI 0.43–0.86), whereas it was similar in DCR (96.4% vs. 96.3%) and OS (HR = 0.70 95% CI 0.46–1.05). Conclusions: TACE plus sorafenib or apatinib was superior to TACE alone for hepatocellular carcinoma with PVTT; no significant advantage was found between TACE+lenvatinib and TACE+sorafenib, although TACE+lenvatinib performed better in terms of ORR and TTP.https://www.mdpi.com/1718-7729/30/1/96hepatocellular neoplasm (HCC)portal vein tumor thrombus (PVTT)transcatheter chemoembolization (TACE)tyrosine kinase inhibitor (TKI)meta-analysis |
| spellingShingle | Jia Deng Ziyue Liao Jian Gao Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis Current Oncology hepatocellular neoplasm (HCC) portal vein tumor thrombus (PVTT) transcatheter chemoembolization (TACE) tyrosine kinase inhibitor (TKI) meta-analysis |
| title | Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis |
| title_full | Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis |
| title_fullStr | Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis |
| title_short | Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis |
| title_sort | efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors for hepatocellular carcinoma patients with portal vein tumor thrombus a systematic review and meta analysis |
| topic | hepatocellular neoplasm (HCC) portal vein tumor thrombus (PVTT) transcatheter chemoembolization (TACE) tyrosine kinase inhibitor (TKI) meta-analysis |
| url | https://www.mdpi.com/1718-7729/30/1/96 |
| work_keys_str_mv | AT jiadeng efficacyoftransarterialchemoembolizationcombinedwithtyrosinekinaseinhibitorsforhepatocellularcarcinomapatientswithportalveintumorthrombusasystematicreviewandmetaanalysis AT ziyueliao efficacyoftransarterialchemoembolizationcombinedwithtyrosinekinaseinhibitorsforhepatocellularcarcinomapatientswithportalveintumorthrombusasystematicreviewandmetaanalysis AT jiangao efficacyoftransarterialchemoembolizationcombinedwithtyrosinekinaseinhibitorsforhepatocellularcarcinomapatientswithportalveintumorthrombusasystematicreviewandmetaanalysis |